The Joint (JYNT) Q2 2026 earnings summary

Executive summary

• Achieved significant progress on the transition to a capital-light, pure-play franchisor model, with major refranchising initiatives nearly complete and renewed focus on growth and profitability.

• Year-over-year improvements included a $560,000 increase in consolidated net income, a $1.4 million rise in adjusted EBITDA from continuing operations, and net income for the first half of 2026 reaching $1.95 million.

• Cash flow from operating activities grew 152% year-over-year, with free cash flow reaching $1.9 million in Q2 2026.

• Best patient retention rate in over five years, driven by flexible and expanded plan options.

• Portfolio optimization and streamlining operations focused on stronger operators and healthier sites.

Financial highlights

• Revenue grew 14% year-over-year to $15.2 million in Q2 2026, with adjusted EBITDA from continuing operations at $1.5 million, up from $88,000 in Q2 2025.

• Consolidated net income increased to $653,000 from $93,000 in Q2 2025; net income for the first half was $1.95 million.

• System-wide sales were $128 million, a decline of 3.7% year-over-year.

• Free cash flow for Q2 2026 was $1.9 million, up from $364,000 in Q2 2025.

• General and administrative expenses decreased to $7.6 million, reflecting improved operating discipline.

Outlook and guidance

• 2026 guidance reiterated: system-wide sales expected between $519 million and $552 million, consolidated adjusted EBITDA between $12.5 million and $13.5 million, and comp sales guidance for 2026 ranges from -3% to +3%.

• New franchised clinic openings expected to be 22–26 for 2026, with total clinic count at year-end lower than 2025 due to closures and refranchising.

• Management anticipates a volatile macroeconomic environment for the remainder of 2026, with ongoing labor shortages and inflationary pressures.